62596-26-3

Basic information

• Product Name: Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester
• Synonyms: Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester;benzyl 4-oxocyclohexanecarboxylate
• CAS NO: 62596-26-3
• Molecular Formula: C₁₄H₁₆O₃
• Molecular Weight: 232.27
• Product Categories: Drug Intermediates
• Mol File: 62596-26-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester(62596-26-3)
• EPA Substance Registry System: Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester(62596-26-3)

Safety Data

• Hazardous Substances Data: 62596-26-3(Hazardous Substances Data)

Usage

Description

Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester is a chemical compound that features a cyclohexane ring with a carboxylic acid group and a phenylmethyl ester group attached. It is recognized for its sweet, fruity aroma and is utilized in various industries for its distinctive scent.
Used in Food Industry:
Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester is used as a flavoring agent for enhancing the taste and aroma of food products, capitalizing on its sweet, fruity scent to create a more appealing consumer experience.
Used in Fragrance and Perfume Industry:
In the realm of fragrances and perfumes, Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester is used as a key ingredient to add a pleasant and distinctive scent to a variety of products, contributing to their overall appeal and attractiveness.
Used in Pharmaceutical Industry:
Cyclohexanecarboxylic acid, 4-oxo-, phenylmethyl ester is utilized as an intermediate in the synthesis of various medications, playing a crucial role in the development of new pharmaceutical compounds.

Upstream product

• 91503-67-2 (±)-benzyl cyclohex-3-ene-1-carboxylate 
• 216106-48-8 4-oxo-bicyclo[3.1.0]hexane-1-carboxylic acid benzyl ester 
• 123762-06-1 benzyl 4-hydroxycyclohexane-1-carboxylate 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 100-39-0 benzyl bromide 
• 99-96-7 4-hydroxy-benzoic acid 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 

Downstream Products

• 916736-77-1 benzyl 4-fluoro-cyclohex-3-ene-1-carboxylate 
• 1346567-57-4 C₁₆H₂₃NO₂ 
• 1346566-99-1 C₁₇H₁₉Cl₂N₅O₄ 
• 1346567-58-5 C₂₄H₂₅Cl₂N₅O₄ 
• 1449661-83-9 benzyl 4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate 
• 1449661-87-3 benzyl 1-hydroxy-4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-enecarboxylate 
• 1449661-84-0 benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate 
• 1449661-88-4 benzyl 1-hydroxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-enecarboxylate 
• 1449661-89-5 benzyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-amino-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)-1-hydroxycyclohex-3-enecarboxylate 
• 1449661-90-8 benzyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)-1-hydroxycyclohex-3-enecarboxylate 
• 1449661-95-3 (R)-benzyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-amino-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)cyclohex-3-enecarboxylate 
• 1449661-96-4 (R)-benzyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(aziridin-1-yl)-5 a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)cyclohex-3-enecarboxylate 
• 1449662-01-4 (S)-benzyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-amino-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)cyclohex-3-enecarboxylate 
• 1449662-03-6 (S)-benzyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-(aziridin-1-yl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)cyclohex-3-enecarboxylate 

Relevant articles and documents

TGF-betaR1 inhibitor and application thereof

The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Tetraoxanes as inhibitors of apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii growth and anti-cancer molecules

New cyclohexylidene 1,2,4,5-tetraoxanes with polar guanidine and urea based groups were synthesized and evaluated for their antimalarial activity against chloroquine resistant and susceptible Plasmodium falciparum strains. The derivatives showed moderate, nM range antimalarial activities and low cytotoxicity. The N-phenylurea derivative 24 exhibited the best resistance indices (RIW2 = 0.44, RITM91C235 = 0.80) and was not toxic against human normal peripheral blood mononuclear cells (IC50 > 200 μM). Seven derivatives were tested in vitro against four human cancer cell lines and they demonstrated high selectivity toward leukaemia K562 cells. One compound, derivative 21 with a primary amino group, was the first tetraoxane tested in vivo against Toxoplasma gondii as another apicomplexan parasite. Subcutaneous administration at a dose of 10 mg kg-1 day-1 for 8 days allowed the survival of 20 % of infected mice, thus demonstrating the high potential of tetraoxanes for the treatment of apicomplexan parasites.